MaxCyte, Inc. (LON:MXCT - Get Free Report)'s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 177 ($2.35) and last traded at GBX 202.77 ($2.70), with a volume of 418041 shares. The stock had previously closed at GBX 192 ($2.55).
MaxCyte Trading Down 1.0 %
The stock's fifty day simple moving average is GBX 246.54 and its two-hundred day simple moving average is GBX 291.86. The firm has a market cap of £254.77 million, a PE ratio of -7.07 and a beta of 1.13. The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
See Also
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
